Digital-enabled hazard screening and sustainable portfolio oversight
Effective chemical portfolio management requires more than individual substance assessments. It demands a structured, scalable approach that combines hazard screening, regulatory insight and digital tools to support informed decision-making across product portfolios.
ARCHE Consulting supports companies and sector organisations in screening, managing and prioritising substance portfolios by combining high-throughput hazard screening methods with expert regulatory interpretation and digital workflow support, including through our collaboration with NextSDS.
Our approach helps organisations identify potential hazards early, anticipate regulatory challenges, and support substitution, prioritisation and sustainability strategies in a consistent and transparent manner.
What we offer
Portfolio-level hazard screening
High-throughput screening of large substance inventories (CAS numbers, IUPAC names, SMILES, etc.) to identify potential human health and environmental hazards at an early stage.
Regulatory-aligned screening and interpretation
Cross-checking substances against authoritative regulatory sources, including the ECHA CLP Inventory and other relevant databases, combined with expert interpretation of regulatory relevance and implications.
Hazard prediction and (eco)toxicity assessment
Use of scientifically robust prediction approaches, including QSAR-based tools (e.g. OECD QSAR Toolbox, VEGA models) and emerging AI-supported methods, to support screening where experimental data are limited.
Digital portfolio management and workflows (NextSDS)
The NextSDS platform helps organise, manage and document chemical portfolio data, enabling efficient handling of screening results and consistent portfolio oversight.
Integrated decision support
Translation of screening outputs into actionable insights to support prioritisation, substitution strategies and sustainable portfolio decision-making, combining digital workflows with expert consultancy.
Why ARCHE Consulting
- Scalable and efficient: high-throughput methods suitable for large and complex portfolios
- Scientifically robust: grounded in recognised methods and expert review
- Regulatory-focused: aligned with current and emerging EU regulatory expectations
- Practical and tailored: screening strategies adapted to your objectives, timelines and regulatory context
Contact our experts:
Karel Viaene
Senior Project Scientist
IBERA Diplomate
karel.viaene@arche-consulting.be
+ 32 9 216 70 34
